Query builder: structured questions over the corpus

Ask structured questions of the corpus: which targets have an approved ADC but no PET tracer, which cancers have no phase-3 product, which companies have products but no institutional link. Combine clauses, negate any of them, and get a linked table.

ModeText mode adds hops: cancer:tnbc -> drugs -> targets

Find

where all of:

linked to a

tagged

Add clause:

Query: targets · has linked treatment with status Approved · has tag adc-target · no tag pet-target

Targets with an approved ADC but no PET tracer

11 targets

Kind	Name	Tags	Links
Target	HER2 A growth-signal receptor. Some cancers make far too much of it, and drugs that block it or use it as a docking site have transformed those cancers.	adc-target, driver	314
Target	MET A receptor that is either mutated in some lung cancers or amplified as an escape route when other lung cancer drugs fail.	driver, kinase, adc-target	98
Target	Claudin 18.2 A tight-junction protein normally hidden in the stomach lining that becomes exposed in gastric and pancreatic cancers.	adc-target, car-t-target	50
Target	CD30 CD30 is a protein on the malignant Reed-Sternberg cells of Hodgkin lymphoma and on some T-cell lymphomas, and the address for the ADC brentuximab vedotin.	adc-target	43
Target	HER3 HER3 is a cousin of HER2 that cancers use as an escape route when HER2 or EGFR are blocked.	adc-target, resistance	40
Target	Folate receptor alpha Folate receptor alpha is a vitamin receptor that ovarian cancer cells carry in large numbers, used as the docking site for the ADC mirvetuximab.	adc-target	30
Target	Nectin-4 Nectin-4 is an adhesion protein plentiful on bladder cancer cells, used as the docking site for the ADC enfortumab vedotin.	adc-target	24
Target	CD22 CD22 is a B-cell surface protein and the docking site for the leukaemia ADC inotuzumab ozogamicin.	adc-target, car-t-target	18
Target	CD33 CD33 is a myeloid surface marker on the blasts of 85 to 90% of acute myeloid leukaemias and on normal myeloid cells, so drugs against it also hit healthy marrow. It is the target of gemtuzumab ozogamicin, the first ADC ever approved (2000), withdrawn in 2010 and re-approved in 2017 at a lower fractionated dose.	adc-target	12
Target	Tissue factor Tissue factor is a clotting protein that cancers abnormally display on their surface, used as an ADC target in cervical cancer.	adc-target	10
Target	CD123 CD123 is the interleukin-3 receptor alpha chain, present on every blastic plasmacytoid dendritic cell neoplasm and on the blasts and leukaemia stem cells of 70 to 80% of acute myeloid leukaemias. Tagraxofusp and pivekimab sunirine target it in that rare neoplasm, and CAR-T cells against it in AML must spare the normal blood-forming progenitors that also carry it.	adc-target	7

Name

Phase / status

Links

HER2

A growth-signal receptor. Some cancers make far too much of it, and drugs that block it or use it as a docking site have transformed those cancers.

314

MET

A receptor that is either mutated in some lung cancers or amplified as an escape route when other lung cancer drugs fail.

Claudin 18.2

A tight-junction protein normally hidden in the stomach lining that becomes exposed in gastric and pancreatic cancers.

CD30

CD30 is a protein on the malignant Reed-Sternberg cells of Hodgkin lymphoma and on some T-cell lymphomas, and the address for the ADC brentuximab vedotin.

HER3

HER3 is a cousin of HER2 that cancers use as an escape route when HER2 or EGFR are blocked.

Folate receptor alpha

Folate receptor alpha is a vitamin receptor that ovarian cancer cells carry in large numbers, used as the docking site for the ADC mirvetuximab.

Nectin-4

Nectin-4 is an adhesion protein plentiful on bladder cancer cells, used as the docking site for the ADC enfortumab vedotin.

CD22

CD22 is a B-cell surface protein and the docking site for the leukaemia ADC inotuzumab ozogamicin.

CD33

CD33 is a myeloid surface marker on the blasts of 85 to 90% of acute myeloid leukaemias and on normal myeloid cells, so drugs against it also hit healthy marrow. It is the target of gemtuzumab ozogamicin, the first ADC ever approved (2000), withdrawn in 2010 and re-approved in 2017 at a lower fractionated dose.

Tissue factor

Tissue factor is a clotting protein that cancers abnormally display on their surface, used as an ADC target in cervical cancer.

CD123

CD123 is the interleukin-3 receptor alpha chain, present on every blastic plasmacytoid dendritic cell neoplasm and on the blasts and leukaemia stem cells of 70 to 80% of acute myeloid leukaemias. Tagraxofusp and pivekimab sunirine target it in that rare neoplasm, and CAR-T cells against it in AML must spare the normal blood-forming progenitors that also carry it.